RECORD // Company

Aclaris Therapeutics, Inc.

Built 2026-11-21T03:56:17Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Aclaris Therapeutics, Inc. · Ctgov · same registered legal name as 'Aclaris Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ACLARIS THERAPEUTICS, INC. · East licences · same registered legal name as 'Aclaris Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001104659-26-123374

ItemValuePeriodFormFiledAccessionReport
Revenue$1,481,0003 months ended 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-21 03:56 UTCReport an error
Net income (loss)$-18,510,0003 months ended 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-21 03:56 UTCReport an error
Cash and cash equivalents$20,394,000at 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-21 03:56 UTCReport an error
Contract liabilities, current$3,966,000at 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-21 03:56 UTCReport an error
Contract liabilities, noncurrent$13,334,000at 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-21 03:56 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001557746
Ticker
ACRS
EIN
460571712
CUSIP
00461U105
Record ID
sx:sec:0001557746

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

37 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 03:56 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 03:56 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 03:56 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 03:56 UTCReport an error
Business address701 LEE ROAD, SUITE 103, WAYNE, PA, 190872026-11-16SEC EDGAR company profile2026-11-21 03:56 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 03:56 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$7,826,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 03:56 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-64,923,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 03:56 UTCReport an error
Total assets (at 2025-12-31)$160,460,0002025-12-3110-K, XBRL Assets2026-11-21 03:56 UTCReport an error
Stockholders' equity (at 2025-12-31)$103,082,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 03:56 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$19,960,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 03:56 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-47,113,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 03:56 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$111,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 03:56 UTCReport an error
Operating lease liabilities (at 2025-12-31)$2,116,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 03:56 UTCReport an error
Form D total offering amount (D filed 2024-12-04)$79,999,9992024-12-04D2026-11-21 03:56 UTCReport an error
Form D total amount sold (D filed 2024-12-04)$79,999,9992024-12-04D2026-11-21 03:56 UTCReport an error
Form D industry groupPharmaceuticals2024-12-04D2026-11-21 03:56 UTCReport an error
Form D revenue rangeDecline to Disclose2024-12-04D2026-11-21 03:56 UTCReport an error
Form D date of first sale2024-11-192024-12-04D2026-11-21 03:56 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-16)On November 16, 2026, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing top line results from its Phase 2 ADMIRATION trial of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin monoclonal antibody, in patients with moderate-to-severe atopic dermatitis (the “Top Line Results”). A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. On November 16, 2026, the Registrant also issued a press release announcing the initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138), an investigational oral inhibitor of interleukin-2-inducible T cell kinase and…2026-11-16SEC EDGAR 8-K 0001104659-26-127478 (text as filed, excerpt)2026-11-21 03:56 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-16)Top Line Results The Top Line Results announced were as follows: The Phase 2 trial did not achieve the primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at Week 24 or secondary endpoints. Pharmacodynamic (PD) results showed robust target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17. Bosakitug was generally well tolerated in the trial. ALPHA Trial The Registrant announced that it expects top line results from the oral erosive lichen planus cohort of the ALPHA Trial in the second half of 2027. Other Announcements The Registrant also announced the following: The Registrant has completed…2026-11-16SEC EDGAR 8-K 0001104659-26-127478 (text as filed, excerpt)2026-11-21 03:56 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended…2026-11-05SEC EDGAR 8-K 0001104659-26-123039 (text as filed, excerpt)2026-11-21 03:56 UTCReport an error
8-K Item 1.01 (filed 2026-10-27)Entry into a Material Definitive Agreement. On October 27, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the underwriters (the “Underwriters”) listed therein, to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share (“Common Stock”) and pre-funded warrants to purchase 6,500,000 shares of Common Stock (the “Pre-Funded Warrants”), in an underwritten offering pursuant to an effective registration statement on Form S-3 (File No. 333-298084) and a related prospectus and prospectus…2026-10-27SEC EDGAR 8-K 0001104659-26-119231 (text as filed, excerpt)2026-11-21 03:56 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-10-27)The information disclosed under the heading “Cash, Cash Equivalents and Marketable Securities as of September 30, 2026” under Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.2026-10-27SEC EDGAR 8-K 0001104659-26-118952 (text as filed, excerpt)2026-11-21 03:56 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-27)On October 27, 2026, Aclaris Therapeutics, Inc. (the “Company”) issued a press release announcing primary analysis results from the Phase 1b proof-of-concept (“POC”) trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis (“AD”) and asthma (the “Results”). The Company also announced it would hold a webcast and conference call with slides related to the Results. A copy of the press release and the presentation that will accompany the webcast and conference call are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Item 9.01…2026-10-27SEC EDGAR 8-K 0001104659-26-118952 (text as filed, excerpt)2026-11-21 03:56 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-27)Cash, Cash Equivalents and Marketable Securities as of September 30, 2026 Based upon preliminary estimates and information available to the Company, it estimates that its cash, cash equivalents and marketable securities were approximately $204.6 million as of September 30, 2026. This amount has not been audited, reviewed, or compiled by the Company’s independent registered public accounting firm. The Company’s actual cash, cash equivalents and marketable securities as of September 30, 2026 may differ from this amount after it completes its comprehensive accounting procedures for the quarter ended September 30, 2026, and any such differences may be material. Primary Analysis Results The…2026-10-27SEC EDGAR 8-K 0001104659-26-118952 (text as filed, excerpt)2026-11-21 03:56 UTCReport an error
Plan (pension, plan no. 001)ACLARIS THERAPEUTICS INC 401(K) PLAN: 118 participants, assets $16,165,4982025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 03:56 UTCReport an error
Largest institutional holder #1 (13F as filed): RA CAPITAL MANAGEMENT, L.P.$67,304,8082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error
Largest institutional holder #2 (13F as filed): BML Capital Management, LLC$63,347,7502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$53,095,7722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error
Largest institutional holder #4 (13F as filed): Deep Track Capital, LP$49,435,0502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error
Largest institutional holder #5 (13F as filed): Vivo Capital, LLC$35,414,6302026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$30,776,5112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error
Largest institutional holder #7 (13F as filed): Frazier Life Sciences Management, L.P.$26,055,2282026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error
Largest institutional holder #8 (13F as filed): Rock Springs Capital Management LP$22,908,5142026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error
Largest institutional holder #9 (13F as filed): ADAGE CAPITAL PARTNERS GP, L.L.C.$21,535,5902026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error
Largest institutional holder #10 (13F as filed): Decheng Capital LLC$21,380,7832026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 03:56 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.